Assembly Biosciences - ASMB Stock Forecast, Price & News

Assembly Biosciences, Inc., a clinical-stage biotechnology company, discovers and develops therapeutic candidates for the treatment of hepatitis B virus (HBV) infection in the United States. The company's lead product candidate is Vebicorvir, which as completed Phase 2 clinical trials to treat patients with chronic HBV infection. It is also developing ABI-H3733 that has completed Phase 1a clinical study, and ABI-4334, which is in pre-clinical trials for the treatment of HBV. The company has collaboration agreements with BeiGene, Ltd. and Arbutus Biopharma Corporation; and Antios Therapeutics, Inc. to evaluate a triple combination treatment in patients with chronic hepatitis B virus infection. It also has strategic license agreements with Indiana University Research and Technology Corporation; and Door Pharmaceuticals, LLC. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California.

Analyst Ratings Changes

ASMB has been the topic of several recent analyst reports. HC Wainwright cut their price objective on shares of Assembly Biosciences from $3.50 to $2.50 in a report on Thursday, July 21st. StockNews.com raised shares of Assembly Biosciences from a "sell" rating to a "hold" rating in a research note on Tuesday, May 24th. Three analysts have rated the stock with a hold rating and two have given a buy rating to the company's stock. According to MarketBeat.com, Assembly Biosciences has a consensus rating of "Hold" and an average target price of $7.90.

Assembly Biosciences Stock Performance

Shares of ASMB opened at $2.17 on Thursday. Assembly Biosciences has a one year low of $1.32 and a one year high of $3.94. The stock has a 50-day moving average price of $2.11 and a 200 day moving average price of $1.89. The company has a market capitalization of $104.63 million, a P/E ratio of -0.77 and a beta of 0.70.

Assembly Biosciences (NASDAQ:ASMB - Get Rating) last released its earnings results on Tuesday, August 9th. The biopharmaceutical company reported ($0.51) EPS for the quarter, missing the consensus estimate of ($0.47) by ($0.04). As a group, equities research analysts forecast that Assembly Biosciences will post -1.95 earnings per share for the current fiscal year.

Insider Buying and Selling at Assembly Biosciences

In related news, CEO John G. Mchutchison sold 12,314 shares of Assembly Biosciences stock in a transaction dated Monday, August 8th. The stock was sold at an average price of $2.13, for a total value of $26,228.82. Following the completion of the transaction, the chief executive officer now directly owns 192,515 shares in the company, valued at $410,056.95. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders have sold 18,498 shares of company stock worth $38,708 in the last ninety days. 4.20% of the stock is owned by insiders.